Oftared Logo Banner enfermedades oculares

Publicaciones volver

Burden of illness of bilateral neovascular age-related macular degeneration in Spain.

Tipo: Artículo
Autores: Ruiz-Moreno JM, Coco RM, García-Arumí J, Xu X, Zlateva G.
Títuto Revista: Current Medical Research and Opinion.
Colaboradores: Grupo de Investogación de Oftalmología de la UCLM (RD07/0062/0019); IOBA - Instituto Universitario de OftalmoBiología Aplicada (IOBA)(RD07/0062/0013);Grupo de Investigación Dpto. Oftalmología del Hospital Valle de Hebrón (RD07/0062/0010).
Centro: 02 - UCLM
Curr Med Res Opin. 2008 Jul;24(7):2103-11. Epub 2008 Jun 10.

Burden of illness of bilateral neovascular age-related macular degeneration in Spain.


University of Castilla La Mancha, Albacete, Spain. josemaria.ruiz@uclm.es


BACKGROUND: The burden of illness, including health resource utilization and costs associated with bilateral neovascular age-related macular degeneration (Nv-AMD), was assessed in Spain.

PATIENTS AND METHODS: As part of an international prospective, case-controlled study, 89 Spanish patients with bilateral Nv-AMD were recruited by retina specialists and 96 Spanish control subjects were recruited by general practitioners and ophthalmologists. Physicians recorded clinical data and visual acuity (VA). In a subsequent telephone interview, Nv-AMD patients and controls completed the National Eye Institute Visual Function Questionnaire (NEI VFQ)-25, the EuroQol (EQ-5D), and the Hospital Anxiety and Depression Scale (HADS) questionnaire. Annual vision-related and non-vision-related medical costs and non-medical-related costs were calculated from study-specific questions.

RESULTS: The mean age was 76.2 years for Nv-AMD patients and 61.9 years for control subjects. The adjusted mean (95% CI) NEI VFQ-25 summary score was 51.9 (48.5; 55.4) for Nv-AMD patients and 87.7 (85.5; 89.9) for control subjects (p<0.05). The summary score of Nv-AMD patients decreased significantly with VA declination. Mean direct vision-related medical and non-medical-related costs were significantly greater for Nv-AMD patients than the control subjects, whereas non-vision-related medical costs were similar between groups. The total mean annual resource utilization cost was euro5733 for Nv-AMD patients compared to euro1070 for control subjects (p<0.0001).

CONCLUSIONS: Although the study design is subject to a number of limitations, patients with Nv-AMD in Spain have worse quality of life outcomes, greater depression, and higher healthcare costs as compared with similarly-aged individuals who are not affected by this disease.

PMID: 18547463 [PubMed - indexed for MEDLINE]